Rivaroxaban: Clinical Trials

57 trials of Rivaroxaban, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 completed, 9 unknown, 4 terminated, 3 recruiting. 57 Phase 2, 12 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 257Completed 39, Unknown 9, Terminated 4, Recruiting 3, Active not recruiting 1, Withdrawn 1
Phase 312Completed 5, Unknown 4, Recruiting 2, Terminated 1
Phase 14Completed 3, Unknown 1

Follow Rivaroxaban: new trials by email Literature Review of Rivaroxaban trials Research Report on Rivaroxaban

Trials (filtered) newest first · largest first

All 57 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
Full dose rivaroxaban, Low dose rivaroxaban, Placebo - SVT, Thrombosis
Phase 2 / Phase 3RecruitingOttawa Hospital Research Institute502025-08-062025-08-11
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Rivaroxaban 10 MG, Placebo control - Venous Thromboembolism, Urologic Cancer
Phase 2 / Phase 3RecruitingOttawa Hospital Research Institute1202024-11-042026-11-12
HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)
Rivaroxaban 10mg, acetylsalicylic acid (ASA) 81mg Oral Tablet - Hip Fractures
Phase 2RecruitingUniversity of Calgary2502024-05-212026-10-09
A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets - Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
Phase 2CompletedBeijing Suncadia Pharmaceuticals Co., Ltd2252024-02-162025-07-22
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
Rivaroxaban, Clopidogrel, Aspirin - Ischemic Stroke, Intracranial Atherosclerosis
Phase 2 / Phase 3UnknownThe First Affiliated Hospital with Nanjing Medical University11802023-12-302023-12-21
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
Aspirin 300mg, Metoprolol 25mg, Clopidogrel 75mg - Patent Foramen Ovale, Migraine
Phase 2CompletedChinese Academy of Medical Sciences, Fuwai Hospital10002022-10-152026-04-22
The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery
Non-vitamin K oral anticoagulants (NOACs), Warfarin - Atrial Fibrillation
Phase 2UnknownSt. Paul's Hospital, Canada1002022-10-122024-04-17
DOAC Versus VKA After Cardiac Surgery
Warfarin, Dabigatran, Rivaroxaban - Anticoagulant-induced Bleeding
Phase 2WithdrawnLaval University2022-03-092023-03-13
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
Apixaban, Rivaroxaban - COVID-19
Phase 2UnknownScotmann Pharmaceuticals402022-03-012022-03-10
Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia
Rivaroxaban 15 MG, Acetylsalicylic acid 100mg, Clopidogrel 75 Mg Oral Tablet - Acute Coronary Syndrome, Coronary Artery Ectasia
Phase 2UnknownInstituto Nacional de Cardiologia Ignacio Chavez602021-09-012022-02-10
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
Rivaroxaban, Warfarin - Antiphospholipid Syndrome, Systemic Lupus Erythematosus
Phase 2CompletedUniversity College, London432021-07-092026-05-22
Rivaroxaban in Type 2 Myocardial Infarctions
Rivaroxaban 2.5 MG [Xarelto], Placebo - Type II Myocardial Infarction
Phase 2 / Phase 3CompletedUniversity of Alberta82021-04-052023-03-27
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Abelacimab, Rivaroxaban - Atrial Fibrillation (AF), Stroke
Phase 2Active not recruitingAnthos Therapeutics, Inc.12872021-02-022025-11-06
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet - Venous Thromboembolism, Anticoagulant-induced Bleeding
Phase 2 / Phase 3CompletedInstituto Mexicano del Seguro Social582021-01-032022-08-25
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
Enoxaparin, Rivaroxaban - Covid19
Phase 2CompletedSt. David's HealthCare1502020-12-012021-06-30
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Rivaroxaban, Standard Of Care (SOC) - COVID-19
Phase 2TerminatedCharite University, Berlin, Germany1112020-11-302022-01-12
A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
Rivaroxaban, Placebo - COVID-19
Phase 2TerminatedGates Medical Research Institute4972020-09-022021-10-22
Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)
Rivaroxaban 2.5 Mg Oral Tablet, Rivaroxaban placebo tablets - Stroke, Prevention
Phase 2 / Phase 3CompletedMazandaran University of Medical Sciences422020-08-222023-10-19
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19
Phase 2 / Phase 3UnknownMedical University of Vienna5002020-04-162021-03-02
Study of Rivaroxaban for CeREbral Venous Thrombosis
Rivaroxaban, Standard of care - Cerebral Venous Thrombosis
Phase 2CompletedUniversity of British Columbia552019-03-122022-12-14

Showing 20 of 57. Sign in to see all of them.

Conditions studied

Venous Thromboembolism (12)  ·  Atrial Fibrillation (6)  ·  Stroke (6)  ·  COVID-19 (5)  ·  Thrombosis (5)  ·  Venous Thrombosis (5)  ·  Ischemic Stroke (4)  ·  Pulmonary Embolism (4)  ·  Acute Coronary Syndrome (3)  ·  Hemorrhage (3)  ·  Cardiovascular Diseases (2)  ·  Coronavirus Infections (2)  ·  Embolism (2)  ·  Embolism and Thrombosis (2)  ·  Heart Valve Diseases (2)

Sponsors

Bayer (14)  ·  Ottawa Hospital Research Institute (3)  ·  Asan Medical Center (2)  ·  Insel Gruppe AG, University Hospital Bern (2)  ·  Portola Pharmaceuticals (2)  ·  Anthos Therapeutics, Inc. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beijing Suncadia Pharmaceuticals Co., Ltd (1)  ·  Capital Medical University (1)  ·  Charite University, Berlin, Germany (1)  ·  Chinese Academy of Medical Sciences, Fuwai Hospital (1)  ·  First Affiliated Hospital Xi'an Jiaotong University (1)  ·  Gates Medical Research Institute (1)  ·  Hanyang University Seoul Hospital (1)  ·  Hospital Geral Roberto Santos (1)

Countries

Canada (15)  ·  United States (12)  ·  Netherlands (11)  ·  Austria (10)  ·  Israel (9)  ·  Italy (9)  ·  Poland (9)  ·  France (8)  ·  Germany (8)  ·  Belgium (7)  ·  Brazil (7)  ·  Australia (6)  ·  Hungary (6)  ·  Spain (6)  ·  Sweden (6)

Top investigators

Alexandra Arias Mendoza, MD (1)  ·  Andre Duraes, PhD (1)  ·  Athena Sharifi-Razvi (1)  ·  Bernd Jilma, MD (1)  ·  Byung-Woo Yoon, PhD (1)  ·  Choonghyoek Choi (1)  ·  Diego Araiza Garaygordobil, MD, MSc (1)  ·  Edward Chafizadeh, MD (1)  ·  Esteban Gandara, MD (1)  ·  Eung-Gyu Kim, PhD (1)

Results publications

PMID 31420317, PMID 31535314, PMID 35244208, PMID 15189396, PMID 15842354, PMID 18094721, PMID 18621928, PMID 19539361, PMID 20637084, PMID 21570509, PMID 22409262, PMID 23903204, PMID 25346499, PMID 25925992, PMID 26458895, PMID 26986753, PMID 26995378, PMID 27075710, PMID 28325638, PMID 28892526, PMID 30293126, PMID 30903459, PMID 31141104, PMID 31837559, PMID 32092140, PMID 32674675, PMID 33045224, PMID 33150497, PMID 33196155, PMID 33502773, PMID 33660875, PMID 34172290, PMID 34473343, PMID 34582035, PMID 35141170, PMID 35904750, PMID 35935856, PMID 36220325, PMID 36413425, PMID 37227726, PMID 37591523, PMID 37675613, PMID 38109984, PMID 39615618, PMID 39842011, PMID 40037214, PMID 40269760, PMID 40546068, PMID 41637102, PMID 42213637

NIH funding

2014 (3), 2004 (1), 2008 (1), U01HL117659 (1)